about
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia PatientsSalvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastomaEfficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population.Angiogenesis in chronic myeloproliferative diseases.SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferationOverexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity.Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.
P50
Q28552532-238199D4-F5E2-4E92-929D-AACD96A5731FQ33414239-A2848B67-DD3F-424A-87CB-BDC4CDF57FCDQ33436471-8F8E37FE-01E4-431D-8F35-65C0B28D1A60Q33441917-B54050C7-C442-458E-84A6-E4DEF5BFF614Q33603472-DB4C7857-F12C-4E3E-A9C1-29A196D38A50Q33889439-EDF78366-55D7-465E-85DB-8E812361C203Q34255507-2BD0FE5C-E77B-4D68-A150-ABE68E2F5B32Q34389277-C60FBA6A-C79D-4C11-B558-6CABFEACFE07Q34508961-B5218084-B7C6-4448-94EF-9979D1AAB9DEQ34577489-16ED9EEF-7362-4A49-838B-A4E263510EA8Q34775933-6BC2BC97-2C8F-4097-BD82-917DBC9FAC08Q34949109-9194B753-AE68-4E00-949C-D113B5018321Q35236063-13CCC4EA-4899-4C74-A292-BFBC08DF28F9Q37441528-C733D48D-3815-4F3A-A717-9F596528BE02Q38341497-5F10B34F-95E3-4223-BFCD-72377BBD6CE2Q38343983-AB83954C-B3CD-4F8F-8729-C67ED7D22B4CQ38882194-58BD7FCE-F35C-4ECF-B3E1-AE663B440E67Q39612979-49D24190-3B45-4DE8-A873-D2701B10FEB6Q39870660-A027EB64-2F32-4C7D-8645-B2F70EC2C8CCQ39928926-1C96A89D-026C-4232-A9EC-340E72A30947Q40788034-13372340-1129-4BE8-8125-AE57F4F28961Q43534642-479242D2-BE00-48D7-A981-01DA03F735EFQ43647238-092D4E78-5D7B-4546-99A0-EEC7F0960E9BQ44338484-42B32605-8B46-4BA2-8DEE-36825751E9C8Q44850006-0EE4B891-86CC-4A98-803A-69433BAACA4FQ45236578-D34E917D-B241-4D22-A934-A8DB599CBCF9Q46419725-B8FF3475-1640-47BA-AF80-8EB4CC3D63ABQ47172060-FD1EB517-EE02-4E86-8D1C-46661557A7E9Q47195200-6190EA23-EFB6-4122-8FE0-315BA9AF4269Q47206497-CE42ED24-426B-4552-B8DF-0406D97F1AA5Q47699163-779C0C5D-582E-4462-AEB5-7063361BC5A8Q47804783-010B6C61-357B-440E-BFF6-AD55FA993EE6Q48154447-9412D80E-5955-4296-878B-63BCFD985F2DQ50016986-A2B6C009-D344-4176-8627-CF19B2B318DBQ50864223-E27C035B-2889-41CB-8B63-E463ECB9ABD2Q51037023-FBF37090-D901-4076-9D90-5B33443580CFQ51412158-FA96266D-A20D-4DD8-BE88-80A5DD8A6680Q53218157-90A38FA5-124B-45BD-95F1-3491CD10D003Q53690201-274E761E-5FDF-453E-81F2-ABEEB2F29723Q54790089-B507D02B-1414-4BDC-84B0-FED99AFDA97B
P50
description
researcher ORCID ID = 0000-0003-1859-6319
@en
name
Giuseppe Alberto Palumbo
@ast
Giuseppe Alberto Palumbo
@en
Giuseppe Alberto Palumbo
@es
Giuseppe Alberto Palumbo
@nl
type
label
Giuseppe Alberto Palumbo
@ast
Giuseppe Alberto Palumbo
@en
Giuseppe Alberto Palumbo
@es
Giuseppe Alberto Palumbo
@nl
prefLabel
Giuseppe Alberto Palumbo
@ast
Giuseppe Alberto Palumbo
@en
Giuseppe Alberto Palumbo
@es
Giuseppe Alberto Palumbo
@nl
P1153
55635724900
P21
P31
P496
0000-0003-1859-6319